close
Asian

AstraZeneca immunotherapy wins first approval in bladder cancer

reuters125-ca2bfe880cfaf1d7cb9394a7274d50479b0c4e0b

(Reuters) – U.S. regulators have approved AstraZeneca’s key immunotherapy drug durvalumab as a treatment for bladder cancer, marking the first commercial green light for a product the company hopes will go on to sell billions of dollars.

admin

The author admin

Leave a Response